Basilea Pharmaceutica AG Allschwil
SWB:PK5
Basilea Pharmaceutica AG Allschwil
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 143 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 143 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
